HCW Biologics Inc. (HCWB)
| Market Cap | 7.38M |
| Revenue (ttm) | 6.59M |
| Net Income (ttm) | -18.12M |
| Shares Out | 7.16M |
| EPS (ttm) | -5.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 481,345 |
| Open | 0.946 |
| Previous Close | 1.120 |
| Day's Range | 0.900 - 1.080 |
| 52-Week Range | 0.250 - 7.350 |
| Beta | 2.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About HCWB
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a... [Read more]
Financial Performance
In 2025, HCW Biologics's revenue was $54,232, a decrease of -97.89% compared to the previous year's $2.57 million. Losses were -$22.30 million, -25.73% less than in 2024.
Financial StatementsNews
HCW Biologics announces 1-for-6 reverse stock split
HCW Biologics (HCWB) announced that its board has approved a 1-for-6 reverse stock split of the company’s common stock, par value $0.0001, which will be effective at 12:01 a.m. Eastern…
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements fr...
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on June 18, 2026, providing details about a securities offering with the SEC.
HCW Biologics announces data from first two dose cohorts of HCW9302 trial
HCW Biologics (HCWB) announced a preliminary human data readout for the first two dose cohorts from its dose-escalating Phase 1 clinical trial of HCW9302, an IL-2 based fusion immunotherapeutic, in…
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All particip...
HCW Biologics Transcript: AGM 2026
Key milestones included $17.5M equity raised, debt repayment, and clinical trial progress. Five shareholder proposals were approved, including director elections, auditor ratification, and warrant-related actions. Strategic focus remains on advancing clinical programs and business development.
HCW Biologics registers to sell 5.69M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 5.69M shares of common stock. The company is not selling any…
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on June 8, 2026, providing details about a securities offering with the SEC.
HCW Biologics price target raised to $5 from $2 at Maxim
Maxim raised the firm’s price target on HCW Biologics (HCWB) to $5 from $2 and keeps a Buy rating on the shares. The company has taken several steps to improve…
HCW Biologics CEO buys $160K in common stock
In a regulatory filing, HCW Biologics (HCWB) disclosed at its CEO Hing bought 113,879 shares of common stock on May 22nd in a total transaction size of $160K. Shares are…
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therape...
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sol...
3 Penny Stocks to Watch Now, 5/21/26
HCW Biologics ($HCWB), MetaVia ($MTVA), and Silexion Therapeutics ($SLXN) are the three penny stocks to watch on May 21, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to low-pri...
HCW Biologics announces pricing of $4M private placement
HCW Biologics (HCWB) announced the pricing of its private placement of an aggregate of 2,846,975 units at a purchase price of $1.405 per unit priced at-the-market under Nasdaq rules to…
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immun...
Why Is Penny Stock HCW Biologics (HCWB) Up Today?
HCW Biologics stock rallied on Friday alongside a strong earnings report.
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fu...
HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia
HCW Biologics (HCWB) announced that its scientists and academic collaborators at Queen’s University at Kingston, Ontario discovered that HCW11-040, a second-generation, pembrolizumab-based fusion immu...
HCW Biologics Quarterly report: Q1 2026
HCW Biologics has published its Q1 2026 quarterly earnings report on May 14, 2026.
HCW Biologics Earnings release: Q1 2026
HCW Biologics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion imm...
HCW Biologics Proxy statement: Proxy filing
HCW Biologics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
HCW Biologics to file IND for HCW11-018b in first half of 2027
HCW Biologics (HCWB) announced major development regarding its tetra-valent, second-generation T-Cell Engager Program based on its TRBC platform technology, which was presented at the poster session a...
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities